Read Full Article
NEWTON, Mass. -- Karyopharm Therapeutics Inc. , a clinical-stage pharmaceutical company, today announced the appointment of J. Scott Garland, Senior Vice President and Chief Commercial Officer of Relypsa ...
Scott brings nearly 25 years of commercial leadership to Karyopharm from his experience at Genentech, Amgen, Merck, Exelixis and now at Relypsa.
I see significant opportunity in Karyopharm's approach to developing first-in-class cancer treatments through nuclear transport targets.